دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Concealed Cardiomyopathy in Autopsy-Inconclusive Cases of Sudden Cardiac Death and Implications for Families
Julia C. Isbister, MBBS,a,b,c Natalie Nowak, BANV ETB IOSC ,a,c Laura Yeates, BS C, G RADD IPG ENC OUNS,a,b,c,d,e Emma S. Singer, BM ED SC ,a,b Raymond W. Sy, MBBS, PHD, b,c Jodie Ingles, P HD, MPH,b,c,d,e Hariharan Raju, MBC HB, P HD, b,f Richard D. Bagnall, P HD, a,b Christopher Semsarian, MBBS, P HD, MPH
doi : 10.1016/j.jacc.2022.09.029
Volume 80, Issue 22, 29 November 2022, Pages 2057-2068
Genetic testing following sudden cardiac death (SCD) is currently guided by autopsy findings, despite the inherent challenges of autopsy examination and mounting evidence that malignant arrhythmia may occur before structural changes in inherited cardiomyopathy, so-called “concealed cardiomyopathy� (CCM).
Expanding the Molecular Autopsy to Uncover Occult Cardiomyopathy: Concealed to Revealed
Ravi Karra, MD, MHS, a,b Navid A. Nafissi, MD
doi : 10.1016/j.jacc.2022.09.030
Volume 80, Issue 22, 29 November 2022, Pages 2069-2071
Transcatheter Edge-to-Edge Mitral Valve Repair in Patients With Severe Mitral Regurgitation and Cardiogenic Shock
Trevor Simard, MD, a Sreek Vemulapalli, MD, b,c Richard G. Jung, MD, PH D, d Andrew Vekstein, MD, b,c Amanda Stebbins, MS, b,c David R. Holmes, MD,a Andrew Czarnecki, MD, MS C, e Benjamin Hibbert, MD, P HD, d Mohamad Alkhouli, MD
doi : 10.1016/j.jacc.2022.09.006
Volume 80, Issue 22, 29 November 2022, Pages 2072-2084
Data on the efficacy of transcatheter edge-to-edge repair (TEER) in patients with cardiogenic shock (CS) are limited.
Transcatheter Treatment of Mitral Regurgitation in Cardiogenic Shock: Promises and Pitfalls∗
Philipp Lurz, MD, PHD, Christian Besler, MD
doi : 10.1016/j.jacc.2022.09.028
Volume 80, Issue 22, 29 November 2022, Pages 2085-2088
2-Year Outcomes of Angiographic Quantitative Flow Ratio-Guided Coronary Interventions
Lei Song, MD, a, * Bo Xu, MBBS,a,b, * Shengxian Tu, P HD, c Changdong Guan, MS C, a Zening Jin, MD, d Bo Yu, MD, e Guosheng Fu, MD, f Yujie Zhou, MD,g Jian’an Wang, MD,h Yundai Chen, MD, i Jun Pu, MD,j Lianglong Chen, MD, k Xinkai Qu, MD,l Junqing Yang, MD, m Xuebo Liu, MD,n Lijun Guo, MD,o Chengxing Shen, MD,p Yaojun Zhang, MD, q Qi Zhang, MD,r Hongwei Pan, MD,s Rui Zhang, MD,a Jian Liu, MD,t Yanyan Zhao, MS C, u Yang Wang, MS C, u Kefei Dou, MD, a Ajay J. Kirtane, MD, SM,v Yongjian Wu, MD, a William Wijns, MD, PH D, w Weixian Yang, MD, a Martin B. Leon, MD,v Shubin Qiao, MD,a Gregg W. Stone, MD,x on behalf of the FAVOR III China Study Group
doi : 10.1016/j.jacc.2022.09.007
Volume 80, Issue 22, 29 November 2022, Pages 2089-2101
In the multicenter, randomized, sham-controlled FAVOR (Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous Intervention in Patients with Coronary Artery Disease) III China trial, quantitative flow ratio (QFR)–based lesion selection improved 1-year clinical outcomes compared with conventional angiographic guidance for percutaneous coronary intervention (PCI).
Angiography-Based Measurement of Myocardial Ischemia: Will Simpler Be Better?
Michael E. Farkouh, MD, MSC ,a Verghese Mathew, MD
doi : 10.1016/j.jacc.2022.10.012
Volume 80, Issue 22, 29 November 2022, Pages 2102-2103
Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease
Neil A. Zakai, MD, a,b Jessica Minnier, PHD, c Monika M. Safford, MD,d Insu Koh, P HD, a Marguerite R. Irvin, PHD, e Sergio Fazio, MD, PH D, f Mary Cushman, MD, a,b Virginia J. Howard, PHD, e Nathalie Pamir, PH D
doi : 10.1016/j.jacc.2022.09.027
Volume 80, Issue 22, 29 November 2022, Pages 2104-2115
Plasma lipids are risk factors for coronary heart disease (CHD) in part because of race-specific associations of lipids with CHD.
HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity?
Keith C. Ferdinand, MD
doi : 10.1016/j.jacc.2022.10.007
Volume 80, Issue 22, 29 November 2022, Pages 2116-2118
A Practical Approach to Left Main Coronary Artery Disease: JACC State-of-the-Art Review
Laura J. Davidson, MD, a, * Joseph C. Cleveland, MD, b,y Frederick G. Welt, MD,c, * Saif Anwaruddin, MD,d, * Robert O. Bonow, MD,a Michael S. Firstenberg, MD,e,y Mario F. Gaudino, MD, f,y Bernard J. Gersh, MB CHB, DPHIL ,g Kendra J. Grubb, MD, MHA, h,y Ajay J. Kirtane, MD, SM, i, * Jacqueline E. Tamis-Holland, MD,j Alexander G. Truesdell, MD,k, * Stephan Windecker, MD,l Roza A. Taha, MBC HB, a S. Chris Malaisrie, MD, a,y On behalf of the ACC’s Interventional and Cardiac Surgery Leadership Councils
doi : 10.1016/j.jacc.2022.09.034
Volume 80, Issue 22, 29 November 2022, Pages 2119-2134
The treatment of left main (LM) coronary artery disease (CAD) requires complex decision-making. Recent clinical practice guidelines provide clinicians with guidance; however, decisions regarding treatment for individual patients can still be difficult.
2022 ACC Health Policy Statement on Career Flexibility in Cardiology: A Report of the American College of Cardiology Solution Set Oversight Committee
doi : 10.1016/j.jacc.2022.08.748
Volume 80, Issue 22, 29 November 2022, Pages 2135-2155
Strain on Palliative Care Services May Limit Resources for Advanced Heart Failure Patients
Daniel A. Ricketti, MD, MBA, MS Casey L. Krickus, BA
doi : 10.1016/j.jacc.2022.08.809
Volume 80, Issue 22, 29 November 2022, Page e201
Tackling Palliative Care in Advanced Heart Failure
José Carlos Arévalo Lorido, PhD Prado Salamanca Bautista, PhD Francesc Formiga, PhD Manuel Méndez Bailón, PhD Óscar Aramburu Bodas, PhD
doi : 10.1016/j.jacc.2022.08.808
Volume 80, Issue 22, 29 November 2022, Pages e203-e204
Reply: Early Integration of Specialist Palliative Care in Advanced Heart Failure: A Multipronged Approach
Yuchieh Kathryn Chang, DO John A. McClung, MD Larry A. Allen, MD, MHS Jennifer Philip, PhD, MBBS *David Hui, MD, MSc
doi : 10.1016/j.jacc.2022.09.033
Volume 80, Issue 22, 29 November 2022, Pages e205-e206
